1. Racial differences in propranolol enantiomer kinetics following oral dosing were previously documented in our laboratory. The purpose of this study was to more completely describe propranolol kinetics in black and white subjects with the goal of gaining a better understanding of the mechanism(s) responsible for racial differences in oral propranolol kinetics. 2. Twelve white and 13 black hea...

The effects of propranolol (DL-propranolol) and D-propranolol on thyroid hormone metabolism were studied in six euthyroid volunteers receiving L-thyroxine (T4) and six hypothyroid patients receiving T4 replacement. D-propranolol as well as propranolol decreased L-triiodothyronine (T3) concentrations and the ratio of T3 to T4 in the euthyroid subjects, and D-propranolol decreased these variables...

The metabolism of propranolol was examined by using microsomes from Dark Agouti rats known as a poor-metabolizer animal model for debrisoquine 4-hydroxylation and Wistar rats. Propranolol 4- and 5-hydroxylations followed biphasic Michaelis-Menten kinetics, and 7-hydroxylation and N-desisopropylation were monophasic in both strains. The kinetic studies showed that the Vmax for propranolol 7-hydr...

[This corrects the article on p. 213 in vol. 22, PMID: 25009702.].

Cirrhosis is the final stage of chronic liver disease caused by fibrosis which decreases function and changes shape structure liver. Portal hypertension an essential pathophysiology cirrhosis, can lead to increased risk death in patients resulting very detrimental complications originating from portal obstruction blood flow, such as cirrhosis or blockage vessels. According EASL guidelines, non-...

Propranolol has been found to have a protective effect in experimental myocardial ischemia. Protection of ischemic kidneys was subsequently demonstrated following treatment with propranolol and its weaker beta blocking isomer, d-propranolol. The objective of the present investigation was to study the effects of propranolol (i.e., racemic d,1 mixture) and d-propranolol upon regional cerebral blo...

there are many evidences that human serum paraoxonase activity modifies plasma lipid profile and paraoxonase has an antiatherogenic property. non-selective beta-blockers affect plasma lipid profile too, but they have atherogenic property when patients take these drugs in long term. in this study the effect of propranolol, a non-selective beta-blocker, on paraoxonase activity was investigated. l...

Propranolol was introduced as a 0-adrenergic receptor antagonist, having about ten times the potency of pronethalol against isoprenaline (Black, Crowther, Shanks, Smith, and Dornhorst, I964) while being devoid of intrinsic sympathomimetic activity. A preliminary investigation with systemic racemic propranolol intravenously and by mouth showed that it caused a lowering of ocular tension in patie...

BACKGROUND Previous work has implicated noradrenergic beta-receptors in the consolidation and reconsolidation of conditioned fear. Less is known, however, about their role in fear expression and extinction. The beta-receptor blocker propranolol has been used clinically to reduce anxiety. With an auditory fear conditioning task in rats, we assessed the effects of systemic propranolol on the expr...

Chronic dopamine replacement therapy in Parkinson's disease (PD) leads to deleterious motor sequelae known as L-DOPA-induced dyskinesia (LID). No known therapeutic can eliminate LID, but preliminary evidence suggests that dl-1-isopropylamino-3-(1-naphthyloxy)-2-propanol [(±)propranolol], a nonselective β-adrenergic receptor (βAR) antagonist, may reduce LID. The present study used the rat unilat...